SCHEMBL4049759

SCHEMBL4049759

CCn1c(=O)ccc2cc(O)ccc21

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CDK4 P11802 2/20 0.44
CCND1 P24385 2/20 0.44
CCND2 P30279 2/20 0.44
CCND3 P30281 2/20 0.44
POLB P06746 1/20 0.43
BTK Q06187 1/20 0.42
EGFR P00533 4/20 0.40
SCN7A Q01118 1/20 0.39
KCNH2 Q12809 1/20 0.39
ALOX5 P09917 1/20 0.39
RPS6KA5 O75582 1/20 0.38
BRPF1 P55201 2/20 0.38
SRC P12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9310207 0.81 BTK (0.52) KDM4EALDH1A1GAAKMT2ACDK4
SCHEMBL30798989 0.79 BTK (0.42) KDM4EALDH1A1GAAKMT2ACDK4
SCHEMBL17576257 0.79 BRPF1 (0.62) KDM4EMEN1ALDH1A1GAAKMT2A
SCHEMBL9367980 0.79 BTK (0.42) KDM4EALDH1A1GAAKMT2ACDK4
SCHEMBL9161052 0.78 KMT2A (0.52) KDM4EMEN1ALDH1A1GAAKMT2A
SCHEMBL4049057 0.77 GRIK1 (0.55) KDM4EKMT2ASMN1; SMN2CDK4CCND1
SCHEMBL9124674 0.77 ALOX5 (0.42) KDM4EALDH1A1GAAKMT2ACDK4
SCHEMBL1238373 0.77 BRPF1 (0.62) EGFRBRPF1
SCHEMBL19495463 0.76 MAPK9 (0.45) BTK
SCHEMBL17576256 0.74 CYP1A2 (0.61) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B KDM4E 260/4885MEN1 2905/4885ALDH1A1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.